



John D. Chodera and Vijay S. Pande

Pande group, Department of Chemistry, Stanford University

Isothermal titration calorimetry (ITC)





Only method that simultaneously provides estimates of both ΔG and ΔH .

Some reactions have no measurable change in heat, and are not measurable by ITC.

Curvature changes with binding affinity


tighter binding gives higher curvature, limiting effective measurement range:

$$0.1 < [P]_T/K_d < 1000$$

for $[P]_T \sim 10$ uM, this limits practical K_d range from 10 nM - 100 uM (5 - 11 kcal/mol)

because they are determined by very different features, ΔG , ΔH , and $T\Delta S$ may have very different (and coupled) uncertainties

What are the real uncertainties in Δ G, Δ H, and $T\Delta$ S? How are they related?



Binding model

simple association is described by equilibrium dissociation constant

$$K_d = \exp[\beta \Delta G_b](1\,M) = \frac{[P]_n[L]_n}{[PL]_n} \quad \text{(in units of molarity M)}$$

concentrations after n injections $[P]_n, [L]_n, [PL]_n$ are determined by solving nonlinear equations given additional constraints on total quantity of ligand and protein:

$$L_n=n\Delta V[L]_s=V_n([L]_n+[PL]_n)$$
 total quantity of ligand in cell after n injections $P=V_0[P]_0=V_n([P]_n+[PL]_n)$ total quantity of protein in cell (constant)

input output
$$n, \beta, \Delta G, P, \Delta V, V_0 \longrightarrow [P]_n, [L]_n, [PL]_n$$

These equations can be solved to produce an analytical solution:

$$V_n[PL]_n = \frac{1}{2} \left\{ (V_n K_d + L_n + P) - \left[(V_n K_d + L_n + P)^2 - 4L_n P \right] \right\}^{1/2}$$

Binding thermodynamics

binding can either liberate heat (exothermic) or consume heat (endothermic):

$$P + L \stackrel{\Delta H}{\rightarrow} PL$$

the heat evolved can be written as

$$Q_n = \Delta H \cdot V_n [PL]_n + n \Delta H_0 \qquad \text{heat potential}$$

$$q_n^* = Q_n - Q_{n-1} \qquad \qquad \text{heat liberated on injection } n$$

where

 ΔH enthalpy of binding

 ΔH_0 heat of dilution / mechanical heat

 $[PL]_n$ concentration of complex after injection n

 $V_n = V_0 + n\Delta V$ volume of solution in cell after injection n

$$p(\theta|\mathcal{D}) \propto p(\mathcal{D}|\theta)p(\theta)$$

 \mathcal{D} data

 θ model parameters

 $p(\theta|\mathcal{D})$ posterior

 $p(\mathcal{D}|\theta)$ sampling distribution (model)

 $p(\theta)$ prior

$$p(\theta|\mathcal{D}) \propto p(\mathcal{D}|\theta)p(\theta)$$

 \mathcal{D} data


heta model parameters

 $p(\theta|\mathcal{D})$ posterior

 $p(\mathcal{D}|\theta)$ sampling distribution (model)

 $p(\theta)$ prior

$$\mathcal{D} = \{q_1, q_2, \dots, q_N\}$$
 measurements of evolved heat



$$p(\theta|\mathcal{D}) \propto p(\mathcal{D}|\theta)p(\theta)$$

 ${\cal D}$ data heta model parameters

 $p(\theta|\mathcal{D})$ posterior $p(\mathcal{D}|\theta)$ sampling distribution (model)

 $p(\theta)$ prior

 $\theta = \{\Delta G, \Delta H, T\Delta S, \Delta H_0\}$

 $\Delta G = -kT \ln K_a$ ΔH $T\Delta S$ ΔH_0

thermodynamic parameters

free energy of binding enthalpy of binding entropic contribution to binding heat of dilution

$$p(\theta|\mathcal{D}) \propto p(\mathcal{D}|\theta)p(\theta)$$

$$\begin{array}{ll} \mathcal{D} & \mathrm{data} & p(\mathcal{D}|\theta) = \prod_{n=1}^N \frac{1}{\sqrt{2\pi}\sigma} \exp\left[-\frac{(q_n-q_n^*)^2}{2\sigma^2}\right] \text{ Gaussian error model} \\ \theta & \mathrm{model parameters} \\ p(\theta|\mathcal{D}) & \mathrm{posterior} & q_n & \mathrm{measured heat of injection } n \\ p(\mathcal{D}|\theta) & \mathrm{sampling distribution (model)} & \sigma & \mathrm{std dev of error in measured heat} \\ p(\theta) & \mathrm{prior} & P+L \overset{\Delta H}{\to} PL \\ q_n^* = Q_n - Q_{n-1} & Q_n = \Delta H \cdot V_n[PL]_n + n\Delta H_0 & \mathrm{heat potential} \end{array}$$

concentrations after n injections $[P]_n, [L]_n, [PL]_n$ determined by solving nonlinear equations given $\beta, \Delta G, P, n, \Delta l, V_n$

$$L_n = n\Delta l[L]_s = V_n([L]_n + [PL]_n) \ \ \text{total quantity of ligand in cell after n injections}$$

$$P = V_0[P]_0 = V_n([P]_n + [PL]_n) \ \ \ \text{total quantity of protein in cell (constant)}$$

$$K_a = \exp[-\beta\Delta G] = \frac{[PL]_n}{[P]_n[L]_n} \ \ \text{binding model}$$

$$p(\theta|\mathcal{D}) \propto p(\mathcal{D}|\theta)p(\theta)$$

 \mathcal{D} data heta model parameters $p(heta|\mathcal{D})$ posterior

 $p(\mathcal{D}|\theta)$ sampling distribution (model)

 $p(\theta)$ prior

 $p(\Delta G, \Delta H, \Delta H_0, \sigma) \propto \sigma^{-1}$ Jeffreys prior

 $\Delta G, \Delta H, \Delta H_0$


can be of any sign and value


 $\sigma>0$ scale parameter; can be of any magnitude (Later, could build in some *a priori* knowledge of instrument error or calibration runs.)

$$p(\theta|\mathcal{D}) \propto p(\mathcal{D}|\theta)p(\theta)$$


$$\begin{array}{ll} \mathcal{D} & \text{data} & p(\theta|\mathcal{D}) = (2\pi)^{-N/2}\sigma^{-(N+1)} \exp\left[-\frac{1}{2\sigma^2}\sum_{n=1}^N (q_n-q_n^*)^2\right] \text{ posterior} \\ p(\theta|\mathcal{D}) & \text{posterior} \\ p(\mathcal{D}|\theta) & \text{sampling distribution (model)} \\ p(\theta) & \text{prior} \end{array}$$


Consider the case of acetyl pepstatin binding to HIV-1 protease.







The fit of each model to the data can be examined.






We can compute **marginal posterior probability distributions** for each thermodynamic parameter to assess the uncertainty.








[Inhibitor]_T/[HIV-1 PR]_T

High-affinity ligands can be troublesome


Ligands with very high binding affinity cause increase in thermogram curvature.



Lack of information near inflection point means that, even though enthalpy (Δ H) can still be accurately extracted, binding affinity (Δ G) becomes extremely uncertain.

Competition with a weaker ligand helps resolution

Competing off a weaker ligand of known affinity can give much more precise binding affinity (ΔG).



KNI-764

Velazquez-Campoy A, Kiso Y, and Friere E. Arch. Biochem. Biophys. 390:169, 2001.

Binding model for competitive binding

Suppose we have M ligands that all bind competitively

$$P + L^{(1)} \stackrel{K^{(1)}}{\rightleftharpoons} PL^{(1)}$$

$$P + L^{(2)} \stackrel{K^{(2)}}{\rightleftharpoons} PL^{(2)}$$

•••

$$P + L^{(M)} \stackrel{K^{(M)}}{\rightleftharpoons} PL^{(M)}$$

We can solve the system of nonlinear equations numerically for concentrations $[P]_n, [L^{(m)}]_n, [PL^{(m)}]_n$

total ligand
$$L_n^{(m)} = n\Delta V[L^{(m)}]_s = V_n([L^{(m)}]_n + [PL^{(m)}]_n) \qquad m = 1, 2, \dots, M$$
 total protein
$$P = V_0[P]_0 = V_n([P]_n + \sum_{m=1}^M [PL^{(m)}]_n)$$
 binding model
$$K_d^{(m)} = \exp[\beta \Delta G_b^{(m)}] = \frac{[P]_n[L^{(m)}]_n}{[PL^{(m)}]_n} \qquad m = 1, 2, \dots, M$$

What are the advantages of the Bayesian method?

Simple to understand!

Easy to incorporate new binding models.

Don't necessarily need a baseline "blank" experiment if parameters can be estimated accurately enough from a single run.

Can accurately represent the true posterior joint distribution of all thermodynamic parameters, regardless of the data.

Confidence intervals and marginal distributions? No problem!

Information content of given datasets, expected information content of new experiments

Make joint inferences from data from multiple experiments

Experimental design:

"Will experiment X give me enough information to make it worthwhile?"

"What is the best experimental design to reduce the uncertainty in Z?"


"Do I have to run a baseline for sample X?"

Making joint inferences from multiple experiments

$$P + L_0 \rightleftharpoons PL_0$$

$$P + L_1 \rightleftharpoons PL_1 \qquad P + L_2 \rightleftharpoons PL_2$$

$$PL_0 + L_1 \rightleftharpoons L_0 + P + L_1 \rightleftharpoons PL_1 \qquad PL_0 + L_2 \rightleftharpoons L_0 + P + L_2 \rightleftharpoons PL_2$$



We can use all data simultaneously to determine $\Delta \Delta G = \Delta G_2 - \Delta G_1$

Velazquez-Campoy A, Kiso Y, and Friere E. Arch. Biochem. Biophys. 390:169, 2001. Lafont V, Armstrong AA, Ohtaka H, Kiso Y, Azmel LM, and Freire E. Chem Biol. Drug Des. 69:413, 2007.

Neglected sources of error: The known unknowns

pipetting errors in preparation of samples

errors in the known concentration or activity of samples

variability in the syringe injection volume

separation of heat of dilution into mechanical (stirrer/injector) heat + dilution

need better model for heat of dilution that depends on injection volume

Binding of charged ligands not so straightforward?

Consider the binding of a charged ligand to a charged protein

$$P^+B^- + A^+L^- \stackrel{K}{\rightleftharpoons} P^+L^- + A^+B^-$$

- Counterions A and B are present because macroscopic systems must be electrically neutral.
- Counterions are dissolved in solution.

We fit this with a model like

$$K' = \frac{[P^+L^-]}{[P^+B^-][A^+L^-]}$$

But a more correct model would be

$$K = \frac{[P^+L^-][A^+B^-]}{[P^+B^-][A^+L^-]} = K' \cdot [A^+B^-]$$

So measured free energies are salt concentration dependent from a purely Le Chatalier's principle effect!

$$\Delta G = \Delta G' + kT \ln \frac{[A^+B^-]}{1M}$$